Pharmaceutical

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract cancer (BTC).

Jun 3, 2025 - 06:00
Zymeworks’ zanidatamab gains approval in China for biliary tract cancer
China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract cancer (BTC).
Read the original article

Tags:

Previous Article

ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I

Next Article

Unveiling the Secret Mechanisms of Ice Formation: How Ice Builds Layer by Layer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Alfasigma opens new doors in the US with Intercept acquisition

Alfasigma opens new doors in the US with Intercept acqu...

Nov 8, 2023

Opinion: The airline industry needs some disaster management lessons. Health care can help

Opinion: The airline industry needs some disaster manag...

Aug 1, 2023

Novartis plans to axe 680 employees

Novartis plans to axe 680 employees

Apr 11, 2024